Specifications tableSubjectMedicine and DentistrySpecific subject areaOncologyType of dataTables and FiguresHow data were acquiredData were obtained from scheduled clinical assessments and adverse event monitoring. Case report forms (CRF) for each patient were captured by study-site personnel from the source documents onto an electronic CRF (Electronic Data Capture).Data formatRaw, analyzed and descriptive dataParameters for data collectionData were collected and analyzed according to prior PLD therapy.\
Described in the Statistical Analysis Plan available in a public repository: <https://clinicaltrials.gov/ProvidedDocs/11/NCT01846611/SAP_001.pdf>Description of data collectionIn the phase 3, randomized, open-label active-controlled study, women patients with platinum-sensitive advanced-relapsed epithelial ovarian, primary peritoneal, or fallopian tube cancer were stratified based on their prior PLD therapy. This subgroup analysis examined the safety and efficacy endpoints including overall survival, progression-free survival and objective response rate in platinum-sensitive patients with prior PLD therapy who participated in this study comparing combination therapy of trabectedin and PLD vs PLD alone in third line setting of recurrent ovarian cancer.Data source locationData were collected at 117 sites in 10 countries: United States (59 sites), Russian Federation (21 sites), Australia (8 sites), Israel (8 sites), United Kingdom (7 sites), China (5 sites), South Africa (4 sites); New Zealand (2 sites); Poland (2 sites); Switzerland (1 sites).Data accessibilityRepository name: ClinicalTrials.gov\
Data identification number: NCT01846611\
Direct URL to data: <https://clinicaltrials.gov/ct2/show/results/NCT01846611?term=ovc3006&draw=2&rank=1>Related research articleMonk BJ, Herzog TJ, Wang G, et al. A phase 3 randomized, open-label, multicenter trial for safety and efficacy of combined trabectedin and pegylated liposomal doxorubicin therapy for recurrent ovarian cancer. Gynecol Oncol. 2020;156(3):535-544. <https://doi.org/10.1016/j.ygyno.2019.12.043>

Value of the data {#sec0001}
=================

•The data from this pre-stratified exploratory analysis provide insights on the potential benefits of pegylated liposomal doxorubicin (PLD) as retreatment in combination with trabectedin vs monotherapy in patients with recurrent ovarian cancer (ROC).•Clinicians and researchers in oncology and other allied fields may find the data useful to improve patients' outcome in ROC setting.•Additional statistical analyses can be performed, or the study can be reproduced for further research in this clinical setting.

1. Data description {#sec0002}
===================

In a global phase 3 registration study, we performed a pre-stratified exploratory analysis to evaluate the impact of prior pegylated liposomal doxorubicin (PLD) on response rates and survival rates. In the protocol-specified un-stratified groups, the objective response rate (ORR) was higher in trabectedin+PLD (T+PLD) (46.0%) vs PLD group (35.9%) (odds ratio \[OR\]: 1.52; 95% CI: 1.07--2.16, *P* = 0.014). However, albeit limited patient numbers, prior PLD therapy did not influence overall survival (OS) or progression-free survival (PFS) between treatment arms ([Fig. 1](#fig0001){ref-type="fig"}, [2](#fig0002){ref-type="fig"}). For T+PLD versus PLD alone, the ORR (OR: 2.06; 95% CI:0.48--9.07; *p* = 0.341), PFS (hazards ratio \[HR\]: 0.63; 95% CI: 0.26--1.48; *p* = 0.281), and OS (HR: 0.93; 95% CI: 0.33--2.60; *p* = 0.894) was similar. Furthermore, prior PLD use did not appear to influence ORR, PFS, or OS within each treatment group ([Table 1](#tbl0001){ref-type="table"}). Combination T+PLD, as expected, elicited greater grade 3/4 treatment-emergent adverse events (TEAEs) than PLD alone, prior PLD therapy did not appear to impact the incidence of grade 3/4 TEAEs within each treatment arm, except for thrombocytopenia for T+PLD ([Table 2](#tbl0002){ref-type="table"}). Use of PLD did not increase the incidences of any PLD-associated toxicities that generally occur after repeated treatment course of PLD, including palmar-plantar erythrodysesthesia, cardiac toxicities, and mucositis.Fig. 1Kaplan--Meier estimates of overall survival by prior PLD use in T+PLD (A) and PLD alone (B).Fig 1Fig. 2Kaplan--Meier estimates for progression free survival by prior PLD use in T+PLD (A) and PLD alone (B).Fig 2Table 1Response rates and survival rates: randomized patients with prior PLD therapy.Table 1**EfficacyT+ PLD \[*****n***** = 289\]PLD monotherapy \[*****n***** = 287\]Prior PLDPrior PLD**Yes (*n* = 19, 6.6%)No (*n* = 270, 93.4%)HR (95% CI)Yes (*n* = 20, 7%)No (*n* = 267, 93%)HR (95% CI)ORR (%)52.645.61.328 (0.468--3.819)35360.959 (0.313 - 2.692)PFS (months)7.17.50.853 (0.435--1.671)5.67.41.212 (0.688--2.135)OS (months)34.222.10.844 (0.409--1.740)28.920.90.713 (0.349--1.458)[^1]Table 2Safety of T+PLD vs PLD by prior PLD therapy use (safety analysis set).Table 2**SafetyT + PLD \[*****n***** = 289\]PLD monotherapy \[*****n***** = 287\]Prior PLDPrior PLD**Yes (*n* = 19, 6.6%)No (*n* = 267, 92.4%)Yes (*n* = 20, 7%)No (*n* = 262, 91.3%)Grade 3/4 TEAEs, n (%)18 (94.7)225 (84.3)14 (70)166 (63.4)Gastrointestinal5 (26.3)50 (18.7)5 (25)50 (19.1) Nausea3 (15.8)18 (6.7)1 (5)3 (1.1) Vomiting3 (15.8)15 (5.6)1 (5)4 (1.5) Diarrhea2 (10.5)3 (1.1)00Hematologic10 (52.6)152 (56.9)3 (15)75 (28.6) Anemia4 (21.1)57 (21.3)1 (5)19 (7.3) Febrile neutropenia2 (10.5)20 (7.5)1 (5)2 (0.8) Neutropenia7 (36.8)117 (43.8)1 (5)58 (22.1) Leukopenia3 (15.8)38 (14.2)020 (7.6) Thrombocytopenia4 (21.1)39 (14.6)03 (1.1)Skin PPE010 (3.7)2 (10)31 (11.8)Cardiac3 (1.1)1 (5)1 (0.4) EF decreased001 (5)0 Atrial fibrillation1 (0.4)1 (0.4) CHF1 (0.4)0[^2]

2. Experimental design, materials, and methods {#sec0003}
==============================================

Women with advanced-relapsed ROC having responded to 2 lines of platinum-based therapy were enrolled. Patients were randomly assigned 1:1 to combined trabectedin and PLD \[trabectedin: 1.1 mg/m^2^, PLD: 30 mg/m^2^, IV, every 3 weeks\] or PLD \[PLD 50  mg/m^2^, IV, every 4 weeks\]. The primary endpoint was OS. Secondary endpoints included PFS and ORR. Stratification was based on prior PLD use (yes or no). ClinicalTrials.gov \#: [NCT01846611](NCT01846611){#interref0004}.
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[^1]: CI, confidence interval; HR, hazard ratio; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PLD, pegylated liposomal doxorubicin; T, trabectedin.

[^2]: CHF, congestive heart failure; EF, ejection fraction; ORR, objective response rate; OS, overall survival; PFS, progression-free survival; PLD, pegylated liposomal doxorubicin; PPE, palmar-plantar erythrodysaesthesia; T, trabectedin; TEAE, treatment-emergent adverse event.
